Departamento de Diagnóstico Oral, Área de Patologia Oral Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas (UNICAMP) Av. Limeira, 901, CEP: 13.414-903, Piracicaba, São Paulo (SP), Brasil
Med Oral Patol Oral Cir Bucal. 2021 Mar 1;26(2):e126-e135. doi: 10.4317/medoral.23974.
The immunohistochemical expression of vascular endothelial growth factor is a prognostic marker in several cancer types. In salivary gland tumors, the association between vascular endothelial growth factor and prognosis remains unclear. The purpose of this study was to perform a systematic review and meta-analysis to assess whether the immunohistochemical expression of vascular endothelial growth factor in patients with salivary gland neoplasms presents prognostic value.
Immunohistochemical studies assessing the predictive value of vascular endothelial growth factor in salivary gland neoplasms were systematically reviewed using PubMed, Scopus, Embase, Cochrane Library, and Web of Science databases. It was assessed any survival rates. The fixed-effect model with an adjusted hazard ratio (HR) and 95% confidence intervals (95% CI) as effect measures were performed in the meta-analysis. The Quality in Prognosis Studies (QUIPS) tool was used to assess the quality of the included studies, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system.
The immunohistochemical overexpression of vascular endothelial growth factor in patients with salivary gland neoplasms was associated with shortened survival (HR=5.37, 95% CI: 2.67-10.83, P = 0.00001). In addition, the presence of vascular endothelial growth factor was tightly associated with tumor size, lymph node metastasis, clinical stage, perineural invasion, vascular invasion, poor local control of the disease, and recurrence.
The immunohistochemical overexpression of vascular endothelial growth factor in patients with salivary gland neoplasms has prognostic value and was associated with decreased survival time. However, more primary well-designed studies are necessary to increase the level of evidence.
血管内皮生长因子的免疫组织化学表达是几种癌症类型的预后标志物。在唾液腺肿瘤中，血管内皮生长因子与预后之间的关系尚不清楚。本研究的目的是进行系统评价和荟萃分析，以评估血管内皮生长因子在唾液腺肿瘤患者中的免疫组织化学表达是否具有预后价值。
使用 PubMed、Scopus、Embase、Cochrane 图书馆和 Web of Science 数据库系统地回顾了评估血管内皮生长因子在唾液腺肿瘤中预测价值的免疫组织化学研究。评估了任何生存率。荟萃分析中采用固定效应模型，调整后的危险比（HR）和 95%置信区间（95%CI）作为效应量。采用预后研究质量（QUIPS）工具评估纳入研究的质量，并采用推荐评估、制定与评估（GRADE）系统评估证据质量。
唾液腺肿瘤患者血管内皮生长因子的免疫组织化学过表达与生存时间缩短相关（HR=5.37，95%CI：2.67-10.83，P=0.00001）。此外，血管内皮生长因子的存在与肿瘤大小、淋巴结转移、临床分期、神经周围侵犯、血管侵犯、疾病局部控制不良和复发密切相关。
唾液腺肿瘤患者血管内皮生长因子的免疫组织化学过表达具有预后价值，并与生存时间缩短相关。然而，需要更多的原始精心设计的研究来提高证据水平。
